Summary: The Centers for Medicare & Medicaid Services modified its coverage policy on Induced Lesions of Nerve Tracts, effective May 15, 2026. Here's what billing teams need to know before that date.
This CMS induced lesions of nerve tracts coverage policy governs Medicare reimbursement for neurosurgical and interventional procedures that deliberately interrupt pain pathways in the nervous system. The policy does not list specific CPT or HCPCS codes in the available documentation — but the clinical scope is narrow and the medical necessity bar is high. If your practice bills for neurolytic procedures, cordotomy, rhizotomy, or related nerve-tract interventions under Medicare, this modification deserves your attention before May 15, 2026.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | CMS (Centers for Medicare & Medicaid Services) |
| Policy | Induced Lesions of Nerve Tracts |
| Policy Code | N/A |
| Change Type | Modified |
| Effective Date | May 15, 2026 |
| Impact Level | Medium-High |
| Specialties Affected | Neurosurgery, Pain Management, Interventional Neurology, Radiation Oncology (stereotactic procedures) |
| Key Action | Audit your charge capture for nerve-tract ablation and neurolytic procedures before May 15, 2026, and confirm your documentation meets updated medical necessity criteria |
CMS Induced Lesions of Nerve Tracts Coverage Criteria and Medical Necessity Requirements 2026
The CMS induced lesions of nerve tracts coverage policy addresses a specific category of procedures: those that permanently or semi-permanently interrupt nerve pathways to treat intractable pain or certain movement disorders. These are not routine nerve blocks. The intent is to destroy or interrupt the tract itself — think cordotomy, tractotomy, myelotomy, or stereotactic ablative procedures targeting central pain pathways.
CMS coverage for these procedures has always hinged on medical necessity. The policy does not cover induced nerve-tract lesions as a first-line treatment. Patients must typically have failed conservative and less-invasive interventions before these procedures are considered medically necessary under Medicare billing guidelines.
The available policy documentation does not include a full text of the updated criteria. However, based on the scope of this policy and CMS's established framework for neurolytic interventions, your documentation needs to show that the patient's condition is refractory, that prior treatments have failed, and that the indication is clinically appropriate. If you are uncertain how the 2026 modification changes the specific threshold language, pull the full policy at the CMS source and compare it against your current documentation templates. Your compliance officer should review that comparison before the effective date of May 15, 2026.
Medical necessity is not a checkbox here. Medicare Administrative Contractors (MACs) scrutinize these claims. A claim denial for insufficient medical necessity documentation on a high-cost neurosurgical procedure is not a minor billing inconvenience — it is a significant revenue and compliance exposure.
CMS Induced Nerve Tract Procedures: What the Policy Likely Governs
Because the policy documentation does not include a detailed policy summary in the available data, it's worth being clear about what this coverage policy category typically encompasses and where the billing risk sits.
Induced lesions of nerve tracts include procedures across several clinical contexts: percutaneous cordotomy for cancer pain, dorsal root entry zone (DREZ) lesioning, commissural myelotomy, cingulotomy, and stereotactic radiosurgical ablation of pain pathways. These procedures share a common billing challenge — they are high-complexity, low-volume, and highly scrutinized for prior authorization and medical necessity.
CMS has historically treated this category as covered under specific, narrow indications — primarily intractable cancer-related pain, intractable non-malignant pain after documented treatment failure, or certain movement and spasticity disorders. Whether the May 2026 modification narrows, expands, or clarifies those indications is not determinable from the available policy data. That uncertainty itself is a risk. If your practice performs these procedures, get the full updated policy text now. Don't wait until a claim comes back denied to find out what changed.
CMS Induced Lesions of Nerve Tracts Exclusions and Non-Covered Indications
CMS does not cover induced nerve-tract lesions for pain conditions where less-invasive treatments have not been tried and documented as failed. That has been a consistent thread across versions of this policy.
Procedures performed without documented refractory status — meaning the patient still has viable, less-destructive options — are not covered. CMS also excludes procedures performed for indications that lack sufficient clinical evidence, which in this space means conditions where the evidence base for ablative nerve-tract intervention is weak or inconsistent.
Because the full updated policy text is not included in the available data for this modification, confirm the complete exclusion list against the published CMS document before May 15, 2026. If you bill for these procedures, your medical director and compliance officer need to see the updated language — not a summary.
Coverage Indications at a Glance
The policy data does not include a structured list of covered and non-covered indications. The table below reflects the general coverage framework for this policy category based on CMS's established approach. Verify each row against the updated policy text before using this as a billing reference.
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Intractable cancer-related pain, failed conservative management | Generally Covered | Not listed in policy data | Medical necessity documentation required; prior authorization likely required by MAC |
| Intractable non-malignant pain, documented treatment failure | Generally Covered (narrow) | Not listed in policy data | High documentation burden; expect scrutiny from MAC on review |
| First-line pain management (no prior treatment failure) | Not Covered | Not listed in policy data | Medical necessity will not be met without documented prior treatment failure |
| Investigational or experimental ablative nerve-tract procedures | Not Covered | Not listed in policy data | Procedures without established evidence base excluded |
| Movement disorders or spasticity (select indications) | Coverage varies | Not listed in policy data | Confirm with MAC; local coverage determination may apply |
CMS Induced Lesions of Nerve Tracts Billing Guidelines and Action Items 2026
This is where the policy change becomes operational for your team. The modification is effective May 15, 2026. That gives you a defined window to act.
| # | Action Item |
|---|---|
| 1 | Pull the full updated CMS policy document now. The available policy data does not include the complete updated text. Access the policy directly at the CMS source before May 15, 2026. Identify every line that changed from the prior version. Don't rely on summaries — this is a high-scrutiny category. |
| 2 | Audit your current documentation templates against updated medical necessity criteria. Your operative notes, clinical records, and prior treatment documentation need to reflect whatever the updated criteria require. If the modification added new documentation requirements, your templates need to match before the effective date. |
| 3 | Check with your MAC on prior authorization requirements. Medicare Administrative Contractors handle prior auth requirements for these procedures at the regional level. A local coverage determination may exist in your region that goes beyond the national policy. Contact your MAC before May 15, 2026 to confirm prior authorization requirements and documentation standards. |
| 4 | Review your charge capture for any nerve-tract ablation procedures. Because this policy does not list specific codes in the available data, your billing team needs to identify which CPT codes in your charge master fall under this policy's scope. Flag those codes for extra review during the transition period. |
| 5 | Train your clinical documentation staff on the updated policy. Claim denial rates on these procedures are driven almost entirely by documentation gaps, not coding errors. Your pain management or neurosurgery team needs to know what CMS now requires — before the first post-May 15 claim goes out. |
| 6 | Talk to your compliance officer before May 15, 2026. This is a high-exposure policy area. If you're not sure how the modification applies to your specific procedure mix or patient population, get your compliance officer involved now. Retrofitting documentation after a denial — or worse, after a post-payment audit — is far more costly than a pre-effective-date review. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Induced Lesions of Nerve Tracts
Codes Listed in the Policy Data
The CMS policy modification for Induced Lesions of Nerve Tracts does not include specific CPT, HCPCS, or ICD-10 codes in the available documentation. No codes are listed in the policy data provided for this change.
Do not rely on this post for a complete code list. Pull the full policy from CMS directly to identify every code in scope.
What Your Billing Team Should Do About Codes
Because the policy data provides no codes, your billing team needs to do internal code identification. Induced nerve-tract lesion procedures in CPT typically fall in the neurosurgery and neurolytic injection ranges. Your coding team likely already knows which codes they bill for these procedures. The action item is to cross-reference those codes against the updated policy language once you have the full document.
If you use a code-level payer policy tool, search for this policy by name or by the CPT codes your practice uses for cordotomy, rhizotomy, DREZ, myelotomy, or stereotactic neurolytic procedures. That search will surface which codes CMS is governing under this policy.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.